

Item Number	Item Name	Description
PTCR1028251	OvCa Targeting TCR (N1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RFC5 (K160N) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RFC5 (K160N) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028252	OvCa Targeting TCR (N2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human BRAP (R543C) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human BRAP (R543C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028253	OvCa Targeting TCR (N3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GINS1 (I87V) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GINS1 (I87V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028254	CRC Targeting TCR (F1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human USP8 (R667H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human USP8 (R667H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR1028255	CRC Targeting TCR (F2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028256	CRC Targeting TCR (F3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NBAS (C144S) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NBAS (C144S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028257	CRC Targeting TCR (F4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SIN3A (N520I) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SIN3A (N520I) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028258	Melanoma Targeting TCR (L1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GANAB (P59S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GANAB (P59S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR1028259	Melanoma Targeting TCR (L2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human EGFLAM (E53K) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human EGFLAM (E53K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282510	Melanoma Targeting TCR (L3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NUF2 (H91L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NUF2 (H91L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282511	Melanoma Targeting TCR (L4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NUF2 (H91L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NUF2 (H91L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282512	Melanoma Targeting TCR (L5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GANAB (P59S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GANAB (P59S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282513	Melanoma Targeting TCR (L6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GANAB (P59S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GANAB (P59S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282514	Melanoma Targeting TCR (L7) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ALT2 (G84D) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ALT2 (G84D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282515	Melanoma Targeting TCR (L8) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ALT2 (G84D) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ALT2 (G84D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282516	Melanoma Targeting TCR (L9) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ALT2 (G84D) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ALT2 (G84D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282517	Melanoma Targeting TCR (L10) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ALT2 (G84D) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ALT2 (G84D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282518	Melanoma Targeting TCR (L11) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GATA6 (Y471S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GATA6 (Y471S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282519	Melanoma Targeting TCR (L12) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GATA6 (Y471S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GATA6 (Y471S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282520	Melanoma Targeting TCR (L13) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GATA6 (Y471S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GATA6 (Y471S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282521	Melanoma Targeting TCR (L14) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GATA6 (Y471S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GATA6 (Y471S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282522	Melanoma Targeting TCR (L15) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GATA6 (Y471S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GATA6 (Y471S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282523	Melanoma Targeting TCR (L16) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human DDX39B (R328C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human DDX39B (R328C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282524	Melanoma Targeting TCR (L17) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RANBP2 (K3185R) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RANBP2 (K3185R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282525	Melanoma Targeting TCR (L18) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RANBP2 (K3185R) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RANBP2 (K3185R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282526	Melanoma Targeting TCR (L19) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RANBP2 (K3185R) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RANBP2 (K3185R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282527	CRC Targeting TCR (F5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human LCP1 (G235R) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human LCP1 (G235R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282528	CRC Targeting TCR (F6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human LCP1 (G235R) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human LCP1 (G235R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282529	CRC Targeting TCR (F7) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human LCP1 (G235R) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human LCP1 (G235R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282530	CRC Targeting TCR (F8) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FN1 (R290C) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FN1 (R290C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282531	CRC Targeting TCR (F9) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FN1 (R290C) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FN1 (R290C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282532	CRC Targeting TCR (F10) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FN1 (R290C) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FN1 (R290C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282533	CRC Targeting TCR (F11) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TNRC18 (A466T) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TNRC18 (A466T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282534	CRC Targeting TCR (F12) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RAPGEF1 (Q60H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RAPGEF1 (Q60H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282535	CRC Targeting TCR (F13) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human LRBA (R2646H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human LRBA (R2646H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282536	NSCLC Targeting TCR (M1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282537	NSCLC Targeting TCR (M2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282538	NSCLC Targeting TCR (M3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human HER2 (Internal Tandem Duplication) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human HER2 (Internal Tandem Duplication) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282539	Lymphoma Targeting TCR (K1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282540	Lymphoma Targeting TCR (K2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282541	Lymphoma Targeting TCR (K3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282542	Lymphoma Targeting TCR (K4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282543	Lymphoma Targeting TCR (K5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282544	Lymphoma Targeting TCR (K6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282545	Lymphoma Targeting TCR (K7) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282546	Lymphoma Targeting TCR (K8) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282547	Lymphoma Targeting TCR (K9) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282548	Lymphoma Targeting TCR (K10) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282549	Lymphoma Targeting TCR (K11) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282550	Lymphoma Targeting TCR (K12) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282551	Lymphoma Targeting TCR (K13) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MyD88 (L265P) antigen on (Lymphoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Lymphoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MyD88 (L265P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282552	GEC Targeting TCR (H1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human DPY19L4 (L143F) antigen on (Gastroesophageal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing GEC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human DPY19L4 (L143F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282553	OvCa Targeting TCR (N4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RNF19B (V372L) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RNF19B (V372L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282554	CRC Targeting TCR (F14) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NUP98 (A359D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NUP98 (A359D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282555	CRC Targeting TCR (F15) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GPD2 (E426K) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GPD2 (E426K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282556	CRC Targeting TCR (F16) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CASP8 (F67V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CASP8 (F67V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282557	CRC Targeting TCR (F17) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282558	CRC Targeting TCR (F18) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SKIV2L (R653H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SKIV2L (R653H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282559	CRC Targeting TCR (F19) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SKIV2L (R653H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SKIV2L (R653H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282560	CRC Targeting TCR (F20) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human H3F3B (A48T) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human H3F3B (A48T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282561	Melanoma Targeting TCR (L20) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human PHKA1 (P34L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human PHKA1 (P34L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282562	Melanoma Targeting TCR (L21) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIF16B (L1009P) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIF16B (L1009P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282563	Melanoma Targeting TCR (L22) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SON (R1927C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SON (R1927C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282564	Melanoma Targeting TCR (L23) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GNB5 (P377L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GNB5 (P377L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282565	Melanoma Targeting TCR (L24) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FBXO21 (S250Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FBXO21 (S250Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282566	Melanoma Targeting TCR (L25) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FBXO21 (S250Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FBXO21 (S250Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282567	Melanoma Targeting TCR (L26) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FBXO21 (S250Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FBXO21 (S250Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282568	Melanoma Targeting TCR (L27) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human FBXO21 (S250Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human FBXO21 (S250Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282569	Melanoma Targeting TCR (L28) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CORO7 (S33L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CORO7 (S33L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282570	Melanoma Targeting TCR (L29) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RECQL5 (P816L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RECQL5 (P816L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282571	Melanoma Targeting TCR (L30) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RECQL5 (P816L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RECQL5 (P816L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282572	Melanoma Targeting TCR (L31) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RECQL5 (P816L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RECQL5 (P816L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282573	Melanoma Targeting TCR (L32) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RECQL5 (P816L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RECQL5 (P816L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282574	Melanoma Targeting TCR (L33) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TFD2 (A270T) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TFD2 (A270T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282575	Melanoma Targeting TCR (L34) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIAA1967 (H277Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIAA1967 (H277Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282576	Melanoma Targeting TCR (L35) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIAA1967 (H277Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIAA1967 (H277Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282577	Melanoma Targeting TCR (L36) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIAA1967 (H277Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIAA1967 (H277Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282578	Melanoma Targeting TCR (L37) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIAA1967 (H277Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIAA1967 (H277Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282579	Melanoma Targeting TCR (L38) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIF16B (L1009P) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIF16B (L1009P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282580	Melanoma Targeting TCR (L39) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIF16B (L1009P) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIF16B (L1009P) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282581	Melanoma Targeting TCR (L40) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SON (R1927C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SON (R1927C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282582	Melanoma Targeting TCR (L41) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SON (R1927C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SON (R1927C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282583	Melanoma Targeting TCR (L42) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SON (R1927C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SON (R1927C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282584	Melanoma Targeting TCR (L43) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SON (R1927C) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SON (R1927C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282585	GEC Targeting TCR (H2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human DLAT (G294L) antigen on (Gastroesophageal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing GEC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human DLAT (G294L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282586	GEC Targeting TCR (H3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human GBAS (E207K) antigen on (Gastroesophageal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing GEC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human GBAS (E207K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282587	GEC Targeting TCR (H4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TMPRSS4 (H233Y) antigen on (Gastroesophageal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing GEC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TMPRSS4 (H233Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282588	GEC Targeting TCR (H5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human PSMD2 (G644A) antigen on (Gastroesophageal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing GEC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human PSMD2 (G644A) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282589	BDC Targeting TCR (A1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human DNAJB1 (Q336R) antigen on (Bile duct cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BDC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human DNAJB1 (Q336R) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282590	CRC Targeting TCR (F21) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282591	CRC Targeting TCR (F22) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282592	CRC Targeting TCR (F23) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282593	CRC Targeting TCR (F24) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282594	CRC Targeting TCR (F25) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282595	CRC Targeting TCR (F26) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282596	Melanoma Targeting TCR (L44) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ASTN1 (P1268L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ASTN1 (P1268L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282597	Melanoma Targeting TCR (L45) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ASTN1 (P1268L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ASTN1 (P1268L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282598	Melanoma Targeting TCR (L46) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ASTN1 (P1268L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ASTN1 (P1268L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282599	Melanoma Targeting TCR (L47) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282600	Melanoma Targeting TCR (L48) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282601	Melanoma Targeting TCR (L49) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282602	Melanoma Targeting TCR (L50) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282603	Melanoma Targeting TCR (L51) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282604	Melanoma Targeting TCR (L52) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CDK4R (R24L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CDK4R (R24L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282605	Melanoma Targeting TCR (L53) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MLL2L (L4743H) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MLL2L (L4743H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282606	Melanoma Targeting TCR (L54) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MLL2 (L4743H) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MLL2 (L4743H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282607	Melanoma Targeting TCR (L55) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SMARCD3 (H24Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SMARCD3 (H24Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282608	Melanoma Targeting TCR (L56) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SMARCD3 (H24Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SMARCD3 (H24Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282609	NSCLC Targeting TCR (M4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ARVCF (H497L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ARVCF (H497L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282610	NSCLC Targeting TCR (M5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ARVCF (H497L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ARVCF (H497L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282611	NSCLC Targeting TCR (M6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SGK223 (L1261Q) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SGK223 (L1261Q) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282612	NSCLC Targeting TCR (M7) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282613	NSCLC Targeting TCR (M8) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282614	NSCLC Targeting TCR (M9) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282615	NSCLC Targeting TCR (M10) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282616	NSCLC Targeting TCR (M11) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248L) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282617	NSCLC Targeting TCR (M12) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CARM1 (R208W) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CARM1 (R208W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282618	NSCLC Targeting TCR (M13) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CARM1 (R208W) antigen on (Non-small cell lung cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing NSCLC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CARM1 (R208W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282619	Melanoma Targeting TCR (L57) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MAGEA6 (E168K) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MAGEA6 (E168K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282620	Melanoma Targeting TCR (L58) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MAGEA6 (E168K) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MAGEA6 (E168K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282621	Melanoma Targeting TCR (L59) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human PDS5A (Y1000F;H1007Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human PDS5A (Y1000F;H1007Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282622	Melanoma Targeting TCR (L60) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MED13 (P1691S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MED13 (P1691S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282623	Melanoma Targeting TCR (L61) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human MED13 (P1691S) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human MED13 (P1691S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282624	Melanoma Targeting TCR (L62) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SYTL4 (S363F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SYTL4 (S363F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282625	Melanoma Targeting TCR (L63) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SYTL4 (S363F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SYTL4 (S363F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282626	Melanoma Targeting TCR (L64) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SYTL4 (S363F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SYTL4 (S363F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282627	Melanoma Targeting TCR (L65) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SYTL4 (S363F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SYTL4 (S363F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282628	Melanoma Targeting TCR (L66) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIF2C (P13L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIF2C (P13L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282629	Melanoma Targeting TCR (L67) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIF2C (P13L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIF2C (P13L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282630	Melanoma Targeting TCR (L68) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NCAPG2 (P333L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NCAPG2 (P333L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282631	CRC Targeting TCR (F27) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282632	CRC Targeting TCR (F28) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282633	CRC Targeting TCR (F29) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282634	CRC Targeting TCR (F30) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282635	CRC Targeting TCR (F31) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282636	CRC Targeting TCR (F32) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282637	CRC Targeting TCR (F33) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282638	CRC Targeting TCR (F34) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282639	CRC Targeting TCR (F35) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282640	EC Targeting TCR (G1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Endometrial cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing EC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282641	EC Targeting TCR (G2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Endometrial cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing EC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282642	BDC Targeting TCR (A2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human ERBB2IP (E805G) antigen on (Bile duct cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BDC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human ERBB2IP (E805G) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282643	BreC Targeting TCR (C1) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282644	BreC Targeting TCR (C2) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282645	BreC Targeting TCR (C3) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282646	BreC Targeting TCR (C4) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282647	BreC Targeting TCR (C5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282648	BreC Targeting TCR (C6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282649	BreC Targeting TCR (C7) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SLC3A2 (K94T, K63T) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SLC3A2 (K94T, K63T) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282650	BreC Targeting TCR (C8) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KIAA0368 (S186F) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KIAA0368 (S186F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282651	BreC Targeting TCR (C9) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CADPS2 (R1266H) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CADPS2 (R1266H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282652	BreC Targeting TCR (C10) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CTSB (D159H) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CTSB (D159H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282653	BreC Targeting TCR (C11) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CTSB (D159H) antigen on (Breast cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing BreC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CTSB (D159H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282654	CRC Targeting TCR (F36) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RAD21 (D162V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RAD21 (D162V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282655	CRC Targeting TCR (F37) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RAD21 (D162V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RAD21 (D162V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282656	CRC Targeting TCR (F38) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human RAD21 (D162V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human RAD21 (D162V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282657	CRC Targeting TCR (F39) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NAV2 (R496Q) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NAV2 (R496Q) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282658	CRC Targeting TCR (F40) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human NAV2 (R496Q) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human NAV2 (R496Q) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282659	CRC Targeting TCR (F41) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R175H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R175H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282660	CRC Targeting TCR (F42) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R175H) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R175H) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282661	CRC Targeting TCR (F43) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (Y220C) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (Y220C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282662	OvCa Targeting TCR (N5) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (Y220C) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (Y220C) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282663	OvCa Targeting TCR (N6) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (G245S) antigen on (Ovarian cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing OvCa tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (G245S) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282664	CRC Targeting TCR (F44) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248W) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282665	CRC Targeting TCR (F45) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248W) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282666	CRC Targeting TCR (F46) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248W) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282667	CRC Targeting TCR (F47) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TP53 (R248W) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TP53 (R248W) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282668	Melanoma Targeting TCR (L69) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282669	Melanoma Targeting TCR (L70) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282670	Melanoma Targeting TCR (L71) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282671	Melanoma Targeting TCR (L72) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282672	Melanoma Targeting TCR (L73) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282673	Melanoma Targeting TCR (L74) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282674	Melanoma Targeting TCR (L75) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282675	Melanoma Targeting TCR (L76) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282676	Melanoma Targeting TCR (L77) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282677	Melanoma Targeting TCR (L78) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human SRPX (P55L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human SRPX (P55L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282678	Melanoma Targeting TCR (L79) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human AHNAK (S4460F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human AHNAK (S4460F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282679	Melanoma Targeting TCR (L80) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human AHNAK (S4460F) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human AHNAK (S4460F) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282680	Melanoma Targeting TCR (L81) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human AFMID (A52V) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human AFMID (A52V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282681	Melanoma Targeting TCR (L82) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human HELZ2 (D614N) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human HELZ2 (D614N) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282682	Melanoma Targeting TCR (L83) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human CENPL (P79L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human CENPL (P79L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282683	Melanoma Targeting TCR (L84) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TPX2 (H458Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TPX2 (H458Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282684	Melanoma Targeting TCR (L85) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human TPX2 (H458Y) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human TPX2 (H458Y) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282685	Melanoma Targeting TCR (L86) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human WDR46 (T300I) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human WDR46 (T300I) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282686	Melanoma Targeting TCR (L87) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human WDR46 (T300I) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human WDR46 (T300I) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282687	Melanoma Targeting TCR (L88) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human WDR46 (T300I) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human WDR46 (T300I) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282688	Melanoma Targeting TCR (L89) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human HIVEP2 (P1682L) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human HIVEP2 (P1682L) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282689	Melanoma Targeting TCR (L90) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human AMPH (E83K) antigen on (Melanoma) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing Melanoma tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human AMPH (E83K) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.

PTCR10282690	CRC Targeting TCR (F48) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282691	CRC Targeting TCR (F49) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282692	CRC Targeting TCR (F50) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12D) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12D) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.
PTCR10282693	CRC Targeting TCR (F51) Expression Plasmid Vector	This plasmid vector is engineered for the expression of a T cell receptor (TCR) that specifically recognizes Human KRAS (G12V) antigen on (Colorectal cancer) tumor cells. It is designed as a versatile tool for constructing either transient or stable cell models expressing CRC tumor-specific TCR, thereby facilitating advanced research in the field of cancer immunotherapy. The plasmid vector enables the generation of engineered T cells capable of selectively identifying and attacking tumor cell types expressing Human KRAS (G12V) , making it highly valuable for studying T cell-mediated cytotoxicity, immune activation mechanisms, and the development of novel adoptive T cell therapies. It serves as a critical component in the development and optimization of TCR-based therapeutic strategies, supporting studies from basic T cell biology to pre-clinical evaluation of engineered T-cell products.